Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adiposity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    124 result(s) found for: Adiposity. Displaying page 5 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2008-008141-37 Sponsor Protocol Number: diab123v1.0 Start Date*: 2009-09-08
    Sponsor Name:Sherwood Forest Hospitals Foundation Trust
    Full Title: Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study
    Medical condition: sleepiness and lethargy among obese patients with diabetes
    Disease: Version SOC Term Classification Code Term Level
    1 10012594 LLT
    1 10029883 LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003432-39 Sponsor Protocol Number: D1690L00016 Start Date*: 2014-11-19
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e...
    Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001628-45 Sponsor Protocol Number: 2.0 Start Date*: 2015-09-09
    Sponsor Name:Dep. of Medical Cell Biology Uppsala University
    Full Title: A parallel, double-blinded, randomized, 6 months, two arms study with lifestyle intervention and exenatide 2 mg once weekly or lifestyle intervention and placebo in adolescents with obesity to expl...
    Medical condition: Obesity in adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010198-19 Sponsor Protocol Number: CLCQ908A2204 Start Date*: 2009-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL ch...
    Medical condition: Obesity and mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021268-13 Sponsor Protocol Number: Letrozole2010-1 Start Date*: 2010-11-19
    Sponsor Name:University College Dublin
    Full Title: The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial
    Medical condition: Obesity Related Male Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029883 Obesity LLT
    12.1 10021011 Hypogonadism male LLT
    Population Age: Adults Gender: Male
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004554-34 Sponsor Protocol Number: 2014-004554-34 Start Date*: 2015-10-15
    Sponsor Name:Bispebjerg Hospital
    Full Title: An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam,...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001661-91 Sponsor Protocol Number: ML19569 Start Date*: 2016-12-09
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents
    Medical condition: Obesity in combination with metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10058097 Metabolic disorder PT
    19.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2007-007970-47 Sponsor Protocol Number: fMRI-Ex-4 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study
    Medical condition: Obesity (N=20) vs. obesity with type 2 diabetes (N=20); Randomised + controlled + cross-over + prospective + double-blind + stratified + 2 arms: Exendin-4 vs NaCl 0.9% iv ober 100 minutes on two s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029885 Obesity, unspecified LLT
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000652-14 Sponsor Protocol Number: L00085 CP 403 Start Date*: 2007-09-28
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Etude en double aveugle versus placebo de l’efficacité et de la tolérance de Cirkan® sur la symptomatologie fonctionnelle veineuse éprouvée (C0s à C3s) par les patientes obèses
    Medical condition: femmes âgées de plus de 18 ans dont le consentement éclairé écrit a été obtenu, affiliées à un régime de sécurité sociale française, non susceptibles d’être enceinte ou de l’être au cours de l’étud...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057320 Venous insufficiency PT
    9.1 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006305-25 Sponsor Protocol Number: 2007-006305-25 Start Date*: 2008-02-15
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome
    Medical condition: Obese adults with Prader Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036476 Prader-Willi syndrome LLT
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002407-10 Sponsor Protocol Number: 17/0238 Start Date*: 2018-03-23
    Sponsor Name:University College London
    Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery.
    Medical condition: Obesity.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10068900 Bariatric surgery LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009278-29 Sponsor Protocol Number: S51477 Start Date*: Information not available in EudraCT
    Sponsor Name:UZ Leuven
    Full Title: Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeningen
    Medical condition: Neuromuscular and neurological diseases, associated with obesity and insulin resistance
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022489 Insulin resistance LLT
    9.1 10022489 Insulin resistance PT
    9.1 10029883 Obesity LLT
    9.1 10065941 Central obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002805-88 Sponsor Protocol Number: J2A-MC-GZGI Start Date*: 2021-09-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities
    Medical condition: Obesity and Overweight with Weight-Related Comorbidities
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000082-72 Sponsor Protocol Number: RC-P0054 Start Date*: 2019-01-03
    Sponsor Name:Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
    Full Title: Study of the communication of the hypothalamus with the periphery: impact of metformin on leptin transport in the cerebrospinal fluid of obese patients. A monocentric prospective study
    Medical condition: OBESITY (BMI > 30)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004452-42 Sponsor Protocol Number: STABIL-NOR Start Date*: 2022-12-14
    Sponsor Name:Helse Bergen HF
    Full Title: An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients (STABIL-NOR –...
    Medical condition: Drug induced weight gain from anti-psychotic drug treatment in patients with schizophrenia. Treatment with semaglutide, a glucagon-like peptide receptor agonist used to treat diabetes and approv...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005317-40 Sponsor Protocol Number: Herlev Start Date*: 2021-05-27
    Sponsor Name:Odense University Hospital - Department of Cardiology
    Full Title: Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): A randomized controlled trial
    Medical condition: Obese patients (BMI >28 kg/m2), aged 60-84 years, with documented cardiovascular disease but no history of diabetes mellitus or heart failure with reduced ejection fraction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006534-40 Sponsor Protocol Number: NN9932-4954 Start Date*: 2022-09-21
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide 25 mg once daily in adults with overweight or obesity (OASIS 4)
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002235-60 Sponsor Protocol Number: NN9536-7545 Start Date*: 2023-02-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006772-38 Sponsor Protocol Number: R256918OBE2001 Start Date*: 2007-10-08
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) NL (Completed) GB (Completed) SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002868-14 Sponsor Protocol Number: CLIK066B2201 Start Date*: 2017-04-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee...
    Medical condition: change in weight in obese or overweight adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 13:00:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA